NMB

AMFA WELCOMES SPIRIT AIRLINES TECHNICIAN AND RELATED EMPLOYEES

Retrieved on: 
Friday, August 26, 2022
Aircraft, NMB, Spirit, National Mediation Board, Spirit Airlines, Aircraft Mechanics Fraternal Association, Nonunion, Maintenance, Human, Mechanics, AMFA, Association, Aviation, Travel, Airline

In early May, Mechanics and Related at Spirit Airlines submitted signed authorization for representation cards from nearly 82% of its workgroup to AMFA, requesting that they file for a representation election with the NMB on behalf of their workgroup.

Key Points: 
  • In early May, Mechanics and Related at Spirit Airlines submitted signed authorization for representation cards from nearly 82% of its workgroup to AMFA, requesting that they file for a representation election with the NMB on behalf of their workgroup.
  • Spirit Airlines Inc.is a major Americanultra-low-cost carrier headquartered inMiramar, Florida, in theMiami metropolitan area.
  • AMFA represents licensed and unlicensed technicians and related employees actively involved in the aviation industry.
  • These technician and related employees work directly on aircraft and/or components, support equipment, and facilities.

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Vial, Vomiting, Nausea, Intellectual property, U.S. Securities and Exchange Commission, CEO, Omicron, Trial of the century, GLOBE, Analgesic, IV, Technology, ASC, Paralysis, NMB, IND, Hospital, Patent, Reversal, Security (finance), Nasdaq, Pain, Marketing, Patient, Hypoventilation, NSAID, COVID-19, Company, Depreciation, Program, Therapy, Meloxicam, Safety, NASDAQ, GAAP, Research, Time, National Railway Company of Belgium, Food, Pharmacokinetics, Constipation, Pharmaceutical industry, Cryptocurrency

MALVERN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today reported financial results for the three and six months ended June 30, 2022, provided key metrics around the ongoing commercialization of ANJESO (meloxicam) injection, updated status of the neuromuscular blocking (NMB) agent development program, and provided an overview of other corporate and financial developments.

Key Points: 
  • ANJESO continued its solid sales performance during the second quarter of 2022 with 49% growth year-over-year, said Gerri Henwood, President and CEO of Baudax Bio.
  • For the second quarter of 2022, ANJESO achieved net product revenue of $0.3 million, reflecting 49% growth year-over-year.
  • In terms of site of care usage of ANJESO, there was a 12% increase in vials sold to hospitals in the second quarter of 2022 compared to the first quarter of 2022.
  • In the second quarter of 2022 the re-order rate from existing accounts was 72%.

Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

Retrieved on: 
Wednesday, June 1, 2022
PK, Time, Intellectual property, NSAID, Plasma protein binding, Patent, Cornell University, Pharmacokinetics, Security (finance), National Railway Company of Belgium, U.S. Securities and Exchange Commission, Pain, Heart rate, Physician, GLOBE, Patient, Hospital, Trial of the century, Intubation, COVID-19, NASDAQ, NMB, Blood pressure, Neuromuscular blocking agents, Patient safety, Anesthesia, Safety, Pharmaceutical industry

This double-blind, placebo-controlled study will investigate single ascending doses of BX2000 administered as an intravenous bolus injection compared to placebo.

Key Points: 
  • This double-blind, placebo-controlled study will investigate single ascending doses of BX2000 administered as an intravenous bolus injection compared to placebo.
  • The study is comprised of up to 10 dosing cohorts and each cohort will enroll 8 patients.
  • The study will evaluate the effect of BX2000 on safety, including heart rate, blood pressure, corrected QT interval, pharmacokinetics, and the time course of the neuromuscular blocking profile.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Analgesic, Neuromuscular blocking agents, Host, NMB, Pain, Omicron, NASDAQ, Pharmacokinetics, GLOBE, Safety, Contract, Patient, Program, Profile, Hospital, Meloxicam, Conference, CEO, Growth, Pharmaceutical industry

MALVERN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today reported financial results for the three months ended March 31, 2022, provided key metrics around the ongoing commercial rollout of ANJESO (meloxicam) injection, updated status of neuromuscular blocking (NMB) agent development program, and provided an overview of other corporate and financial developments.

Key Points: 
  • Given current market conditions, despite the promising trajectory for ANJESO sales, during the first quarter of 2022 Baudax Bio implemented a reduction in force that significantly cut its commercial spend for field personnel and other related expenses.
  • Baudax Bio continues to focus on key accounts, contracts, and working with existing ordering accounts as well as continuing to pursue targeted new ones.
  • Baudax Bio will host a conference call tomorrow, Thursday, May 5, 2022, at 8:30 a.m. Eastern Time, to discuss the first quarter 2022 financial results and recent corporate achievements.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

NMB Financial Corporation/New Millennium Bank Announces Proposal to Acquire Noah Bank and Potential US Treasury ECIP Investment Into NMB Financial Corporation

Retrieved on: 
Thursday, April 14, 2022
Banking, Professional Services, Finance, Board, MDI, Federal, Director, ECIP, COVID-19, Regulation, Organization, Department, Sale, Goal, FDIC, Growth, Treasury, NMB, Prospectus, Company, OTC Markets Group, Department of Treasury and Finance, Communication, Intention, Letter of intent, Letter, WHEN, MDIS, Board of directors, Acquisition, Risk, CDFI, THE, Security (finance), Bank, Noah

NMB is on its way to receive $75.1 million investment through the US Department of Treasurys Emergency Capital Investment Program (ECIP).

Key Points: 
  • NMB is on its way to receive $75.1 million investment through the US Department of Treasurys Emergency Capital Investment Program (ECIP).
  • NMB is one of 186 community development financial institutions (CDFI) and minority depository institutions (MDI) that are eligible to receive $8.7 billion in capital through the ECIP.
  • It is anticipated that the Department of Treasury will be investing $75.1 million in preferred stock of NMB Financial Corporation, with the investment expected to close at the end of May 2022.
  • The investment by the US Department of Treasury is part of the Federal Governments response to the COVID-19 pandemic.

Confidence and Growth Continue for Frank Kuri and Nationwide Mortgage Bankers ('NMB') in 2022

Retrieved on: 
Monday, March 28, 2022
Nationwide Mutual Insurance Company, Series 6, P&C, DBA, Growth, Life, INC, Real estate agent, Kuri, Coldwell, NMLS, Urban planner, Professional, Loan origination, Suite, PEOPLE, Coldwell Banker, Technology, Goal, Williams v Natural Life Health Foods Ltd, NMB, GLOBE, DBA (airline), Education, Prudential Financial, Bank, National Association of Realtors, Real estate, Construction, Health

MELVILLE, N.Y., March 28, 2022 (GLOBE NEWSWIRE) -- Nationwide Mortgage Bankers ("NMB") and Frank Kuri, EVP Branch Development, see increased growth and confidence in 2022.

Key Points: 
  • MELVILLE, N.Y., March 28, 2022 (GLOBE NEWSWIRE) -- Nationwide Mortgage Bankers ("NMB") and Frank Kuri, EVP Branch Development, see increased growth and confidence in 2022.
  • NMB EVP of Branch Development Frank Kuri sees the opportunity and a time to act and capitalize on the company's expanded growth and influence in 2022.
  • Frank Kuri has 30+ years of real estate financial services and mortgage banking experience.
  • Nationwide Mortgage Bankers, Inc. NMLS# 819382 ( www.nmlsconsumeraccess.org ) Equal Housing Lender 3 Huntington Quadrangle, Suite 403N, Melville, NY 11747 | (833) 700-8884 | www.nmbnow.com; "NMBNOW".

HELP Provides Down Payment Assistance to Santa Fe, New Mexico, Artist

Retrieved on: 
Tuesday, March 22, 2022
Construction & Property, Seniors, Finance, Banking, Professional Services, Philanthropy, Fund Raising, Consumer, Other Philanthropy, Residential Building & Real Estate, Housing, Hearing, Federal Home Loan Bank Board, Equal housing lender, Great Recession, Congress, Partnership, Multimedia, New Mexico Bank & Trust Building, Program, National Trust Community Investment Corporation, HELP, NMB, Federal Home Loan Banks, FHLB, Condominium, Gingival recession, FDIC, Music, Bank, Management

Artist Anita L. West lives in Santa Fe, a dream city for many artists, but also an expensive place to live.

Key Points: 
  • Artist Anita L. West lives in Santa Fe, a dream city for many artists, but also an expensive place to live.
  • As rents continued to rise, she began to explore options for buying and connected with a housing assistance agency known as Homewise after hearing about it from a friend.
  • Homewise, in turn, suggested that Ms. West apply for the Homebuyer Equity Leverage Partnership (HELP), a program of the Federal Home Loan Bank of Dallas (FHLB Dallas) in which down payment and closing cost assistance is provided through FHLB Dallas member financial institutions.
  • The HELP funds meant I didnt have to deplete my savings for the down payment, so I still had some reserves and some funds for upgrades, she said.

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

Retrieved on: 
Wednesday, March 16, 2022
Trial of the century, Time, Research, Technology, Workforce, 3D ultrasound, NMB, Mission statement, Patent, Analgesic, National Railway Company of Belgium, Nausea, CEO, ASC, U.S. Securities and Exchange Commission, Breakthrough, Intellectual property, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, Letter, Plasma protein binding, Pain, COVID-19, Growth, Constipation, Compliance, Edmonton Metropolitan Transit Services Commission, Patient, Neuromuscular blocking agents, Therapy, Meloxicam, CPA, Adoption, Reverse stock split, Security (finance), NASDAQ, Principal, Hypoventilation, Sale, Food, Depreciation, NSAID, GLOBE, Three Months Gone, GAAP, FDA, Vomiting, Market for corporate control, Company, Paralysis, Pharmaceutical industry, Cryptocurrency

MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today reported financial results for the fourth quarter and year ended December 31, 2021, provided key metrics around the ongoing commercial rollout of ANJESO® (meloxicam) injection, updated status of its neuromuscular blocking agent (NMB) portfolio, and provided other recent updates.

Key Points: 
  • For the fourth consecutive quarter, demand for ANJESO demonstrated solid growth and deepening usage patterns, with quarterly vials sold to end-users increasing by approximately 32% in the fourth quarter of 2021 compared to the third quarter of 2021.
  • The average quarterly orders per account increased over 23% in the fourth quarter of 2021 versus the third quarter of 2021 and the re-order rate grew to nearly 70% with a deepening usage pattern.
  • Financial Results for the Three Months Ended December 31, 2021
    For the three months ended December 31, 2021, Baudax Bio saw continued quarterly growth in units sold to end users of approximately 32% compared to the third quarter of 2021, totaling approximately 5,000 units sold to end users in the fourth quarter.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

Teamsters Applaud Confirmation Of Deirdre Hamilton To Serve On National Mediation Board

Retrieved on: 
Tuesday, December 7, 2021
National Mediation Board, Congress, Twitter, Knowledge, RLA, Conference, Aircraft, International Brotherhood of Teamsters, Flight, Woman, Dan Sullivan (U.S. senator), Railway Labor Act, NMB, Man, Aviation, Mechanics, Senate, Maintenance, Facebook, Association of Flight Attendants, Association, Airline

WASHINGTON, Dec. 7, 2021 /PRNewswire/ --The Teamsters Union applauds today's confirmation of Deirdre Hamilton to serve as a member on the National Mediation Board (NMB) by the U.S. Senate.

Key Points: 
  • WASHINGTON, Dec. 7, 2021 /PRNewswire/ --The Teamsters Union applauds today's confirmation of Deirdre Hamilton to serve as a member on the National Mediation Board (NMB) by the U.S. Senate.
  • Hamilton has served as the staff attorney for the Teamsters Airline Division for the past six years and at the Association of Flight Attendants for the previous 12 years.
  • "Thanks to today's confirmation, workers across the country in our rail and airline industries have a true champion serving on the board," said Teamsters General President Jim Hoffa.
  • "Ms. Hamilton will be an outstanding member of NMB," said Teamsters Rail Conference Director and Vice President At-Large John Murphy.

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

Retrieved on: 
Thursday, November 11, 2021
Well, Safety, Primate, New Year, Was, Cornell University, National Railway Company of Belgium, Security (finance), NASDAQ, Food, Intubation, Trial of the century, Paralysis, COVID-19, NMB, Anesthesiology, Regulation of tobacco by the U.S. Food and Drug Administration, NSAID, Plasma protein binding, Neuromuscular blocking agents, Pain, Hospital, Company, U.S. Securities and Exchange Commission, GLOBE, Vital signs, Time, Patent, Feedback, Patient, FDA, Surgeon, Intellectual property, Pharmaceutical industry, Wine

MALVERN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced a clinical program update for its neuromuscular blocking agents (NMBs), including completion of a dose-escalation study evaluating BX-1000 in healthy volunteers.

Key Points: 
  • Used together, these agents to allow a very rapid induction of neuromuscular blockade for surgical settings, followed by a rapid reversal of the neuromuscular blockade.
  • Baudax is preparing the clinical study report for this dose-escalation study and expects to submit it to FDA early in the New Year.
  • Used together, these agents allow for a very rapid induction of neuromuscular blockade for surgical settings, followed by a rapid reversal of the neuromuscular blockade.
  • These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.